Article
Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunities
2023-11-23
Abstract excerpt
Abstract Viruses that cause malignancies such as hepatocellular carcinoma and cervical cancer are the cause of approximately 20% of all human cancers. In recent years, engineered T cell immunotherapy targeting tumor‐associated antigens (TAAs) has had some success against virus‐associated cancer, although these treatments are associated with side effects. TAA‐specific‐modified T cells may kill cancer cells but they...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e624491e-384a-5bca-a8c9-df9100483eea
- DOI
- 10.1002/med4.37